Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026

Intellia Therapeutics (Nasdaq: NTLA) will present additional Phase 3 HAELO data for lonvoguran ziclumeran (lonvo-z), a CRISPR-based gene editing therapy for hereditary angioedema, in a late-breaking oral session at the EAACI 2026 Congress in Istanbul.

Rhea-AI Summary

Intellia Therapeutics (Nasdaq: NTLA) will present additional Phase 3 HAELO data for lonvoguran ziclumeran (lonvo-z), a CRISPR-based gene editing therapy for hereditary angioedema, in a late-breaking oral session at the EAACI 2026 Congress in Istanbul.

A related poster will address treatment burdens for HAE patients in Europe.

Argus Jun 1 session

-2.42% close to close Open Argus

Details

News Market Reaction – NTLA

In the Jun 1 session, NTLA declined 2.42%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights that Intellia secured a late-breaking oral slot at EAACI 2026 to showca...

Analysis

This announcement highlights that Intellia secured a late-breaking oral slot at EAACI 2026 to showcase additional Phase 3 HAELO data for lonvo-z in hereditary angioedema, plus a poster on patient burden outside the U.S. It follows earlier positive topline and durability data and ongoing regulatory interactions. Investors may watch for any new efficacy or safety details beyond the previously reported 87% attack reduction and 62% attack- and therapy-free rates, and how these shape the evolving BLA narrative.

Key Figures

EAACI 2026 dates: June 12–15, 2026 Oral presentation time: June 13, 2026; 8:45–9:45 a.m. TRT Poster presentation time: June 12, 2026; 12:00–1:00 p.m. TRT +2 more

EAACI 2026 dates

June 12–15, 2026

European Academy of Allergy & Clinical Immunology Congress

Oral presentation time

June 13, 2026; 8:45–9:45 a.m. TRT

Late-breaking HAELO Phase 3 oral session

Poster presentation time

June 12, 2026; 12:00–1:00 p.m. TRT

HAE treatment burden poster session

Oral presentation number

100217

HAELO Phase 3 late-breaking talk identifier

Poster number

D1.336

HAE burden poster identifier

Previous Clinical trial Reports

5 past events · Latest: Apr 27

Same Type 5 events

1. Apr 27

   Phase 3 HAELO topline

   24h Move

   -4.3%

   Reported strong Phase 3 HAELO efficacy and safety, plus rolling BLA initiation.

2. Apr 24

   Topline readout timing

   24h Move

   -4.3%

   Announced upcoming Phase 3 HAELO topline data and webcast scheduling details.

3. Mar 03

   Longer-term HAE data

   24h Move

   -11.9%

   Presented durable Phase 1/2 lonvo-z data and HAE burden survey at AAAAI 2026.

4. Mar 02

   MAGNITUDE hold lifted

   24h Move

   +12.1%

   FDA lifted clinical hold on MAGNITUDE Phase 3 ATTR-CM trial with safety mitigations.

5. Jan 27

   MAGNITUDE-2 hold lifted

   24h Move

   +6.3%

   FDA lifted clinical hold on MAGNITUDE-2 ATTRv-PN trial and raised enrollment target.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

phase 3, randomised, double-blind, placebo-controlled, +2 more

6 terms

phase 3 medical

"HAELO, a Phase 3, Global, Randomised, Double-Blind, Placebo-Controlled Study"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

randomised medical

"Phase 3, Global, Randomised, Double-Blind, Placebo-Controlled Study of Lonvoguran"

Randomised means participants or items are assigned to different groups by chance rather than choice, like flipping a coin to decide who gets which treatment or process. This matters to investors because it reduces bias and makes outcomes more reliable, helping separate real effects from luck so that claims about a product, treatment, or business change are more trustworthy when assessing risk and value.

double-blind medical

"Phase 3, Global, Randomised, Double-Blind, Placebo-Controlled Study of Lonvoguran"

A double-blind process means that neither the people conducting an activity nor the people involved know certain key details, such as who is receiving a treatment or a placebo. This approach helps prevent bias from influencing the results, making the outcome more trustworthy. For investors, it ensures that decisions or judgments are based on unbiased information rather than preconceived opinions or expectations.

placebo-controlled medical

"Phase 3, Global, Randomised, Double-Blind, Placebo-Controlled Study of Lonvoguran"

"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.

crispr-based gene editing therapy medical

"a CRISPR-Based Gene Editing Therapy, in Patients with Hereditary Angioedema"

A crispr-based gene editing therapy uses a molecular “scissor and guide” system to change a specific piece of DNA inside a patient’s cells, aiming to fix or disable a faulty gene that causes disease. Investors care because these treatments can transform or replace long-term care for certain conditions, offering large potential rewards but also high technical, regulatory and safety risks and long development timelines similar to betting on a breakthrough technology.

hereditary angioedema medical

"lonvo-z (formerly known as NTLA-2002) in hereditary angioedema (HAE)"

A rare inherited disorder that causes sudden, painful swelling under the skin or in internal tissues, including the airway, because a natural blood‑control protein is missing or not working. Attacks can be unpredictable and sometimes life‑threatening, so people often need ongoing medication or emergency treatment. For investors, hereditary angioedema represents a niche but stable market for specialized therapies, diagnostics, and emergency care solutions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that data from the global Phase 3 HAELO clinical trial of lonvo-z (formerly known as NTLA-2002) in hereditary angioedema (HAE) will be presented in a late-breaking oral presentation at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress 2026, taking place June 12-15 in Istanbul, Türkiye. Intellia will also have a poster presentation detailing the burdens experienced by HAE patients living outside the United States.

Late-Breaking Oral Presentation Details:

• Title: HAELO, a Phase 3, Global, Randomised, Double-Blind, Placebo-Controlled Study of Lonvoguran Ziclumeran, a CRISPR-Based Gene Editing Therapy, in Patients with Hereditary Angioedema
  Session: Immune deficiencies and autoimmunity
  Data and Time: Saturday, June 13, 2026, from 8:45 – 9:45 a.m. TRT
  Presentation Number: 100217
  Presenter: Danny Cohn, M.D., Ph.D., Internist, Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Center, University of Amsterdam

Poster Presentation Details:

• Title: Barriers to Normalization with Existing Treatments Among People Living with Hereditary Angioedema in Europe
  Session: Immune deficiencies and autoimmunity 02
  Data and Time: Friday, June 12, 2026, from 12:00 – 1:00 p.m. TRT
  Poster Number: D1.336
  Presenter: Henriette Farkas, M.D., Ph.D., Professor of Allergy and Clinical Immunology Director of the Hungarian Angioedema Center of Reference and Excellence, Department of Internal Medicine and Hematology, Semmelweis University

About Lonvo-z
Based on Nobel Prize-winning CRISPR/Cas9 technology, lonvo-z has the potential to become the first one-time treatment for hereditary angioedema (HAE). Lonvo-z is an in vivo CRISPR gene editing candidate that is intended to permanently lower kallikrein by inactivating the kallikrein B1 (KLKB1) gene with a single dose. Lonvo-z has received five notable regulatory designations: Orphan Drug and RMAT Designation by the U.S. Food and Drug Administration (FDA), the Innovation Passport by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA), Priority Medicines (PRIME) Designation by the European Medicines Agency, as well as Orphan Drug Designation (ODD) by the European Commission.

About Hereditary Angioedema
Hereditary angioedema (HAE) is a rare, genetic disease characterized by severe, recurring and unpredictable inflammatory attacks in various organs and tissues of the body, which can be painful, debilitating and life-threatening. It is estimated that one in 50,000 people are affected by HAE. There are preventative and on-demand treatment options to help manage the condition, including long- and short-term prophylaxis used to prevent swelling attacks. Current treatment options often include lifelong therapies, which may require chronic intravenous (IV) or subcutaneous (SC) administration as often as twice per week or daily oral administration to ensure constant pathway suppression for disease control. Despite chronic administration, breakthrough attacks still occur. Kallikrein inhibition is a clinically validated strategy for the preventive treatment of HAE attacks.

About Intellia Therapeutics
Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.

Investor Contact:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc.
jason.fredette@intelliatx.com

Media Contact:
Mike Tattory
Vice President
LifeSci Communications
mtattory@lifescicommunications.com 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What Phase 3 HAELO data for lonvo-z will Intellia (NTLA) present at EAACI 2026?

Intellia will present additional Phase 3 HAELO data for lonvoguran ziclumeran (lonvo-z) in hereditary angioedema. According to Intellia, results will be shared in a late-breaking oral session focused on immune deficiencies and autoimmunity at EAACI 2026 in Istanbul.

When is Intellia Therapeutics’ late-breaking HAELO oral presentation on lonvo-z at EAACI 2026?

The late-breaking HAELO oral presentation is scheduled for Saturday, June 13, 2026, from 8:45–9:45 a.m. TRT. According to Intellia, the talk will occur in an immune deficiencies and autoimmunity session, with presentation number 100217 and Danny Cohn, M.D., Ph.D., as presenter.

Who will present Intellia’s Phase 3 HAELO data for lonvoguran ziclumeran (lonvo-z) at EAACI 2026?

Danny Cohn, M.D., Ph.D., will present the Phase 3 HAELO oral data on lonvo-z. According to Intellia, he is an internist in the Department of Vascular Medicine at Amsterdam Cardiovascular Sciences, Amsterdam University Medical Center, University of Amsterdam.

What is lonvoguran ziclumeran (lonvo-z) being studied for in the Phase 3 HAELO trial?

Lonvoguran ziclumeran (lonvo-z) is being studied as a CRISPR-based gene editing therapy for hereditary angioedema. According to Intellia, the HAELO study is a global, randomized, double-blind, placebo-controlled Phase 3 trial in patients with hereditary angioedema.

What poster will Intellia (NTLA) present about hereditary angioedema at EAACI 2026?

Intellia will present a poster on barriers to normalization with existing hereditary angioedema treatments in Europe. According to Intellia, the poster focuses on burdens experienced by HAE patients living outside the United States and will be shown in an immune deficiencies and autoimmunity session.

When is Intellia’s hereditary angioedema poster session scheduled at EAACI 2026?

The hereditary angioedema poster session is scheduled for Friday, June 12, 2026, from 12:00–1:00 p.m. TRT. According to Intellia, the poster is numbered D1.336 and will be presented in the Immune deficiencies and autoimmunity 02 session.

Who will present Intellia’s hereditary angioedema treatment burden poster at EAACI 2026?

Henriette Farkas, M.D., Ph.D., will present the hereditary angioedema treatment burden poster. According to Intellia, she is Professor of Allergy and Clinical Immunology and Director of the Hungarian Angioedema Center of Reference and Excellence at Semmelweis University.